Lung Cancer Symptom Assessment and Management Intervention
- HCPs: attending physician, thoracic medical oncologist, expected to work in the
setting for at least 2 years.
- Patients: 21 years of age or older; diagnosis of Stage IIIA, IIIB, IV non-small cell
lung cancer OR limited or extensive stage small cell lung cancer; receiving care in
the out-patient setting; receiving treatment with chemotherapy +/- additional
therapies; English speaking.
- Patients: Any patient who needs emergent care, routine visits scheduled less than
once a month
Type of Study:
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
% completion of intervention use and adherence to suggested symptom management strategies.
Outcome Time Frame:
Mary E. Cooley, PhD
Dana-Farber Cancer Institute
United States: Institutional Review Board
- Lung Cancer
- Symptom Assessment and Management Intervention Program
- Lung Neoplasms
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Boston Medical Center||Boston, Massachusetts 02118|